The discovery could speed up new cancer drugs and make them cheaper to produce, a researcher told Newsweek.
Alzheimer disease is a progressive neurodegenerative disorder that impairs memory and mental function. It is the most common form of dementia, accounting for 60–70% of cases, and its prevalence is ...
The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma ...
The approval by the US Food and Drug Administration (FDA) of the first histone deacetylase (HDAC) inhibitor in October went largely unnoticed. “A quiet event,” Daniel Von Hoff, head of translational ...
As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...
DelveInsight’s 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...
Pancreatic cancer is one of the deadliest cancers and the third-leading cause of cancer-related death in the United States.
Preclinical studies suggest that blocking histone deacetylases, which modulate gene transcription, could potentially treat neurodegeneration, but in practice, the theory has not lived up to its ...
Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results